Palivizumab prophylaxis in 'late preterm' newborns

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 23, Issue SUPPL. 3, 2010, Pages 53-55

  Lanari, Marcello ^a   Silvestri, Michela ^b   Rossi, Giovanni A ^b  

^a Imola Hospital   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

late preterm infants; lower respiratory tract infections; palivizumab; Respiratory syncytial virus; risk factors; risk scoring tools; RSV hospitalization

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

CHILD HOSPITALIZATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FETUS LUNG MATURATION; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LATE PRETERM INFANT; LUNG DISEASE; NEWBORN MORBIDITY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK REDUCTION; SEASONAL VARIATION; EVALUATION; FEMALE; NEWBORN; PREGNANCY; THIRD TRIMESTER PREGNANCY; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PREGNANCY; PREGNANCY TRIMESTER, THIRD; VIRUS DISEASES;

EID: 77957942606     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2010.506757     Document Type: Review

References (35)

1. Kirby RS. Late preterm birth and neonatal outcome: is 37 weeks gestation a threshold level or a road marker on the highway of perinatal risk? Birth 2010;37:169-171.
2. AAP, ACOG. Standard terminology for reporting of reproductive health statistics in the United States. Guidelines for Perinatal Care (5th edition, Appendix E). Elk Grove, IL: American Academy of Pediatrics and American College of Obstetricians and Gynecologists; 2002. pp. 377-394.
3. Heron M, Sutton PD, Xu J, Ventura SJ, Strobino DM, Guyer B. Annual summary of vital statistics: 2007. Pediatrics 2010;125:4-15.
4. Bettegowda VR, Dias T, Davidoff MJ, Damus K, Callaghan WM, Petrini JR. The relationship between cesarean delivery and gestational age among US singleton births. Clin Perinatol 2008;35:309-323.
5. Stephens BE, Vohr BR. Neurodevelopmental outcome of the premature infant. Pediatr Clin North Am 2009;56: 631-646.
6. Darcy AE. Complications of the late preterm infant. J Perinat Neonat Nurs 2009;23:78-86.
7. Mathews TJ, MacDorman MF. Infant mortality statistics from the 2005 period linked birth/infant death data set. Natl Vital Stat Rep 2008;57:1-32.
8. McLaurin KK, Hall CB, Jackson EA, Owens OV, Mahadevia PJ. Persistence of morbidity and cost differences between latepreterm and term infants during the first year of life. Pediatrics 2009;123:653-659.
9. Shapiro-Mendoza CK, Tomashek KM, Kotelchuck M, Barfield W, Nannini A, Weiss J, Declercq E. Effect of latepreterm birth and maternal medical conditions on newborn morbidity risk. Pediatrics 2008;121:e223-e32.
10. Doyle LW, Cheung MM, Ford GW, Olinsky A, Davis NM, Callanan C. Birth weight 51501 g and respiratory health at age 14. Arch Dis Child 2001;84:40-44.
11. Moss TJ. Respiratory consequences of preterm birth. Clin Exp Pharmacol Physiol 2006;33:280-284.
12. Langston C, Kida K, Reed M, Thurlbeck WM. Human lung growth in late gestation and in the neonate. Am Rev Respir Dis 1984;129:607-613.
13. Friedrich L, Stein RT, Pitrez PMC, Corso AL, Jones MH. Reduced lung function in healthy preterm infants in the first months of life. Am J Respir Crit Care Med 2006;173:442-447.
14. Galdes-Sebaldt M, Sheller JR, Grogaard J, Stahlman M. Prematurity is associated with abnormal airway function in childhood. Pediatr Pulmonol 1989;7:259-264.
15. Wang ML, Dorer DJ, Fleming MO, Catlin EA. Clinical outcomes of near-term infants. Pediatrics 2004;114:372-376.
16. Mussi-Pinhata M, Gonçalves AL. Serum immunoglobulin levels and incidence of infection during the first year of life in full-term and preterm infants. J Trop Pediatr 1989;35:147-153.
17. Bont L, Kimpen JL. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis. Intensive Care Med 2002;28:616-621.
18. Willson DF, Landrigan CP, Horn SD, Smouht RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142-S149.
19. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143:S133-S141.
20. Meissner H, Welliver R, Chartrand S, Law B, Weisman L, Dorkin HL, Rodriguez WJ. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;18:223-231.
21. No authors listed. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537.
22. Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003;35:484-489.
23. Figueras AJ, Quero J, Domenech E. Comite de Estandares de la Sociedad Espanola de Neonatologia. Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 2005;63:357-362.
24. Rondini G, Macagno F, Barberi I. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonatologica 2004;1:1-11.
25. Deutsche Gesellschaft fü r Pädiatrische Infektiologie (DGPI) Stellungnahme zur Prophylaxe von schweren RSVErkrankungen bei Risikokindern mit Palivizumab; 2006. Available at (accessed December 2006).
26. American Academy of Pediatrics. Respiratory Syncytial Virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics 2009:560-569.
27. Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UDL, Chezzi1 C; on behalf of the "Osservatorio VRS Study" Group. Four-year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). The New Microbiologica 2006;29:35-43.
28. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23:815-820.
29. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalisation for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23:806-814.
30. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143:S118-S126.
31. Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG. The risk of respiratory syncytial virusrelated hospitalisations in preterm infants of 29 to 35 weeks gestational age. Pediatr Infect Dis J 2006;25:1188-1190.
32. Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, Silvestri M, Pistorio A, Chezzi C; Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166:1267-1272.
33. Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J; European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78-87.
34. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-480.
35. Paes B, Steele S, Janes M, Pinelli J. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks gestational age in Canada. Curr Med Res Opin 2009;25:1585-1591.